1 Hepatitis B Treatment Dr R.V.S.N.Sarma., M.D., Consultant Physician & Chest Specialist.

Slides:



Advertisements
Similar presentations
Hepatitis B & Hepatitis C in HIV
Advertisements

Egyptian Guidelines For Management of Chronic Hepatitis B
HBV and HIV HIV and HBV VG Naidoo Gastroenterology.
The Hepatitis B&C Past and Present Martin J Spitz MD FACP AGAF Clinical Professor of Medicine UCSF.
Geoffrey DUSHEIKO. Nucleosides for HBeAg-positive chronic hepatitis B G Dusheiko Centre for Hepatology Royal Free and University College School of Medicine.
Treatment appropriate Normal or minimal hepatitis Chronic hepatitis Normal or inactive hepatitis Progressive fibrosis Cirrhosis HCC HBeAg Anti-HBe HBV.
Professor George KK Lau The University of Hong Kong Hong Kong SAR, China HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated.
Anna LOK. Management of Antiviral Resistant Hepatitis B Clinical Case Anna S. F. Lok University of Michigan Ann Arbor, MI, USA.
Case study: Chronic HBV infection Marion Peters University of California San Francisco 2009.
Hepatitis web study H EPATITIS W EB S TUDY Therapeutic Agents Used to Treat Hepatitis B Presentation Prepared by: Nina Kim, MD and David Spach, MD Last.
1 3 rd Paris Hepatitis Congress, 20/1/09 HBeAg-positive patient: Why do I treat with nucleos/tide analogs? Samuel S. Lee University of Calgary Calgary,
Patrizia FARCI. Hepatitis Delta Virus Hepatitis B surface antigen (HBsAg) HDV RNA genome Hepatitis delta antigen (HDAg) 36 nm From HDV: From HBV: From.
HCV: Treat now or Defer Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL JUNE 19,
Natural History of Hepatitis B and Liver Cancer Screening Herbert H Lee, M.D., M.P.H., M.S.Ed.
Long-Term Anti-HBV Therapy Considerations Adrian M. Di Bisceglie, MD, FACP Badeeh A. & Catherine V. Bander Chair in Internal Medicine Chairman and Professor.
Coinfection with Hepatitis B and HIV Chia C. Wang Assistant Professor of Medicine AIDS Clinical Conference February 20, 2007.
Robert PERRILLO. 2 nd Paris Hepatitis Conference Why Do I Treat my HBeAg Negative Chronic Hepatitis B Patients with Pegylated Interferon.
Stephanos HADZIYANNIS. Following HBeAg seroconversion a proportion of patients retains or redevelops significant HBV replication associated with persistent.
3 rd Paris Hepatitis Conference January, 20th 2009 How to optimize the management of my HBeAg negative patients? Pietro Lampertico 1st Gastroenterology.
3rd Paris Hepatitis Conference: Morning Session on HBeAg-Neg CHB WHY DO I TREAT MY PATIENTS WITH PEGYLATED INTERFERON? PEGYLATED INTERFERON?
1 FDA Advisory Meeting Clinical Trial Design – Hepatitis B Treatment Anna S.F. Lok, M.D. University of Michigan Ann Arbor, M I.
Rafael ESTEBAN. New Drugs for Chronic Hepatitis B R. Esteban, M.D. Hospital General Universitario Valle de Hebron Barcelona.
CHRONIC HEPATITIS B SEROLOGY. Antigens HBsAg -Found on the surface of the intact virus and in serum as unattached particles -Earliest detectable marker.
Can One Pill A Day Keep Hepatitis B Away? Scott K. Fung, MD, FRCPC Toronto General Hospital University of Toronto November 30, 2009 TGH.
Hepatitis B: Chronic Hepatitis and Inactive Carriers - Management
Hepatitis B and Acute Liver Failure Jack Kuritzky, PGY-2 UNC Internal Medicine Morning Report 3/12/10.
1 Roadmap for Management of Patients with Chronic Hepatitis B (CHB) Prof. Xinxin Zhang Rui Jin Hospital Jiao Tong University.
Clinical Advances in Diagnosis, Treatment and Outcome of Hepatitis A, B and C Marc Ghany, M.D. LDB, NIDDK, NIH Demystifying Medicine May 19th, 2009.
4 th Annual Clinical Care Options for Hepatitis Symposium: HBV Highlights.
George LAU. Hepatitis B e antigen positive patients: Why do I treat my patient with pegylated interferon? 2nd Hepatitis Paris conference George KK Lau,
Hepatitis B Patricia D. Jones, M.D. November 13, 2009.
1. Sustained suppression of HBV replication Decrease in serum HBV DNA to
Hepatitis C+ Recipients: Considerations for Exclusion Emily A. Blumberg, M.D.
Yves BENHAMOU. Management of Patients with HIV/HBV Co-infection Yves Benhamou Hepatology Department Groupe Hospitalier Pitié Salpétrière Paris, France.
HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.
Gui-Qiang Wang Department of Infectious Diseases
Treating HBV Infection: Sustained Remission with Immune control Joseph Sung MD, PhD Department of Medicine and Therapeutics Institute of Digestive Diseases.
Management of Resistance: Implications for Treatment Choices
Vertical Transmission of HBV
Surrogate Endpoints for Hepatitis B Trials Greg Soon, Ph.D Rafia Bhore, Ph.D. Division of Biometrics III/Antiviral 8/7/2002 AC.
MAKATI MEDICAL CENTER Ledesma Hall October 17, 2005 Hepatitis - Interactive Session Roel Leonardo R. Galang, M.D. Fellow, Philippine College of Physicians.
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
Milan J. Sonneveld,1 Bettina E. Hansen, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry.
On-treatment management for chronic hepatitis B (CHB) in patients receiving oral antiviral therapy Byung-Ho Kim Kyung Hee University School of Medicine.
내과스텝강의 국내 만성B형간염의 현황과 치료 전략.
Hadziyannis SJ et al. EASL Peginterferon alfa-2a (40KD) (PEGASYS ® ) in combination with ribavirin (RBV): efficacy and safety results from a phase.
Maria Buti, MD Professor of Medicine Hospital Universitario Vall d'Hebron Barcelona, Spain Clinical Focus: Impact of HBV Therapy on Liver Fibrosis and.
Choosing First-Line Therapy in Chronic Hepatitis B This program is supported by an unrestricted educational grant from.
Clinicaloptions.com/hepatitis Using Virologic and Serologic Tests in the Management of Hepatitis B Diagnose chronic HBV infection When in slideshow mode,
Entecavir Superior to Lamivudine for Treatment of Nucleoside-Naive, HBeAg- Negative Patients Slideset on: Lai CL, Shouval D, Lok AS, et al. Entecavir versus.
Understanding and Implementing the AASLD’s HBV Practice Guidelines* and Other Recent Guidelines and Recommendations on the Diagnosis, Management, and Treatment.
Debate: What Is the Best Rescue Strategy for the Management of Primary Nonresponse: Switch or Add? Jointly sponsored by Postgraduate Institute for Medicine.
بنام خداوند مهربان. دکتر نرگس نجفی دانشیار دانشگاه.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Hepatitis B virus infection in renal transplant recipients
Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:
Treatment of HBV/HCV Coinfection
Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen–Positive Patients with Chronic Hepatitis B : A Randomized International Study of Entecavir.
Evidence-based Treatment for Hepatitis B Infection
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC Treatment Selection for HBV-Infected Patients With Decompensated.
Clinical Focus: Impact of HBV Therapy on Liver Fibrosis and Cirrhosis
Nefrologia dei trapianti
How to optimize the management of my HBeAg negative patients?
Natural history of hepatitis B
Suna Yapali, Nizar Talaat, Anna S. Lok 
GI clinical research 2002–2003: the year in review
Ming-Ling Chang, Yun-Fan Liaw  Journal of Hepatology 
Clinicaloptions.com/hepatitis Using Virologic and Serologic Tests in the Management of Hepatitis B Diagnose chronic HBV infection When in slideshow mode,
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
HEPATITIS B VIRUS ; WHAT`S NEW
Presentation transcript:

1 Hepatitis B Treatment Dr R.V.S.N.Sarma., M.D., Consultant Physician & Chest Specialist

2 TREATMENT OF CHRONIC HEPATITIS B Review of trials and meta-analysis of RCT of Interferon (IFN) and Lamivudine (LAM) Clinical Practice Guidelines Issues for future clinical trials

3 Goals of Antiviral Treatment of Chronic Hepatitis B 1. Sustained suppression of HBV replication Decrease in serum HBV DNA to <10 5 copies/ml HBeAg to anti-HBe seroconversion HBsAg to anti-HBs seroconversion 2. Remission of liver disease Normalization of serum ALT levels Decreased necroinflammation in liver 3. Improvement in clinical outcome Decreased risks of developing cirrhosis, liver failure and HCC Increased survival

4 Lamivudine R x of HBeAg+ CHB Placebo Lam x 52 wk IFN x 16 wk Lam x 24 wk +IFN x 16 wk HBeAg seroconversion at week 52 Lai et al., NEJM 1998 Dienstag et al., NEJM 1999 Schalm et al., Gut

5 Lamivudine R x of HBeAg+ CHB Histologic response at week 52 Placebo Lam x 52 wk IFN x 16 wk Lam x 24 wk. +IFN x 16 wk Dienstag et al., NEJM 1999 Schalm et al., Gut 2000 Lai et al., NEJM

6 Lamivudine Rx of HBeAg+ CHB Normal ALT at Week 52 LAM PLA LAM & IFN IFN

7 Lamivudine Treatment (0-52 Weeks) Lamivudine R x of HBeAg- CHB HBV DNA (pg/mL) ALT (xULN) Normal ALT Tassopoulos et al., Hepatology 1999; 29:889

8 Treatment of HBeAg - CHB Treatment On-Therapy Response Sustained Response IFN (3-6 MU tiw) 6 months60 – 90%10 – 15% > 12 months50 – 75%20 – 25% Lamivudine ( mg) 12 months65 – 80%~10% 24 months50 – 60%? > 36 months30 – 40%? Adefovir 12 months70%?

9 Treatment of Decompensated Cirrhosis Measurements of Response –Viral suppression –Biochemical improvement –Decrease in CTP score (Alb, bil, PT, ascites, encephalopathy) –Decrease clinical complications + –Decrease need for transplant + –Decrease HCC ? –Improve survival +

10 Clinical Practice Guidelines Who to treat What treatment When to stop treatment

11 AASLD Practice Guidelines Current therapy has limited long-term efficacy Careful balance of benefits and risks before treatment is initiated –patients’ age –severity of liver disease –likelihood of response –potential adverse events Lok and McMahon, Hepatology 2001;34:1225

12 + +<2x ULNBoth IFN and Lam low efficacy Observe + +>2x ULNIFN or Lam IFN NR or contraindications  Lam – +>2x ULNIFN or Lam Long-term R x required – –normalNo Rx required +/ – +cirrhosisCompensated: IFN low dose or Lam Decompensated: Lam, optimal timing unknown - Transplant +/ – –cirrhosisCompensated: observe Decompensated: Transplant *HBV DNA in serum >10 5 copies/ml AASLD Practice Guidelines: Rx Strategies HBeAgHBV DNA* ALTTreatment Lok and McMahon, Hepatology 2001;34:1225

13 Finite duration of R x More durable response Resistant mutants not reported Expensive Frequent side effects Long/indefinite duration of R x Resistant mutants Oral administration Negligible side effects Lower costs? Interferon Lamivudine Pros Cons Treatment of Chronic Hepatitis B

14 AASLD Practice Guidelines Treatment Regimen - IFN Dose 5 MU QD or 10 MU tiw SC Duration e + CHB - 16 wk e – CHB - 12 months Lok and McMahon, Hepatology 2001;34:1225

15 AASLD Practice Guidelines Treatment Regimen - Lamivudine Dose 100mg daily po (Lamivir HBV – 100 mg Cipla) HIV Coinfection – 150mg bid + other HIV R x Duration e+ CHB – 1yr... HBeAg seroconversion – Stop R x ? DNA suppression, HBeAg+ - Continue R x ? Breakthrough infection – continue R x if clinically stable? Stop R x if clinical deterioration e- CHB > 1yr, optimal duration? Lok and McMahon, Hepatology 2001;34:1225

16 Impact of HBeAg Clearance on Long-Term Clinical Outcome Month Proportion with complication free survival Niederau et al., NEJM 1996;334: IFN No R x Clearance of HBeAg No Clearance of HBeAg

17 IFN Treatment of HBeAg- Patients Hadziyannis S, et al., J Hepatology 1990; 11(Suppl 1):513 Fattovich G, Hepatology 1992; 15:584 Pastore G, J Hepatology 1992; 14;221 Lampertico p, Hepatology 1997; 26:1621